AREVA Med is Macrocyclics’ parent company since 2011.
AREVA Med is a nuclear biotech company developing innovative therapies in oncology. AREVA Med has developed new processes for producing lead-212 (²¹²Pb), a rare radioactive isotope used in Targeted Alpha Therapy (TAT), an innovative and promising approach of nuclear medicine allowing to recognize and destroy cancer cells while limiting the impact on nearby healthy cells.
With Macrocyclics and Pharma partners, AREVA Med pursues the development of effective therapies to address patients’ needs. AREVA Med is the subsidiary of the AREVA group.
Discover more about AREVA Med at www.AREVAMed.com and in our video: